Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors
Authors
Keywords
-
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 86, Issue 4, Pages 475-486
Publisher
Springer Science and Business Media LLC
Online
2020-09-08
DOI
10.1007/s00280-020-04134-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting DNA repair to drive immune responses: it's time to reconsider the strategy for clinical translation
- (2020) Nobuyuki Takahashi et al. CLINICAL CANCER RESEARCH
- Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer
- (2019) Hanna K. Sanoff et al. Nanomedicine-Nanotechnology Biology and Medicine
- Targeting Topoisomerase I in the Era of Precision Medicine
- (2019) Anish Thomas et al. CLINICAL CANCER RESEARCH
- Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma
- (2019) Keith T. Schmidt et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial
- (2016) S. M. Keefe et al. ANNALS OF ONCOLOGY
- Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling
- (2016) Anne-Gaëlle Dosne et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing
- (2016) Andrew J. Clark et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents
- (2015) Jennifer S Petschauer et al. Nanomedicine
- Translational Impact of Nanoparticle-Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer
- (2014) E. Pham et al. CLINICAL CANCER RESEARCH
- Acidic extracellular microenvironment and cancer
- (2013) Yasumasa Kato et al. Cancer Cell International
- Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors
- (2013) Huali Wu et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies
- (2013) Glen J. Weiss et al. INVESTIGATIONAL NEW DRUGS
- Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle
- (2013) S. Eliasof et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Nathanael L. Dirks et al. CLINICAL PHARMACOKINETICS
- Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin
- (2009) Mark E. Davis ADVANCED DRUG DELIVERY REVIEWS
- Mechanistic Basis of Using Body Size and Maturation to Predict Clearance in Humans
- (2009) Brian J. Anderson et al. Drug Metabolism and Pharmacokinetics
- Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements
- (2009) T. Schluep et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started